Odulimomab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD11a |
Clinical data | |
ATC code | none |
Identifiers | |
CAS Number |
159445-64-4 ![]() |
ChemSpider | none |
![]() ![]() |
Odulimomab is an investigational drug for the prevention of transplant rejection[1][2] and for the treatment of various immunological diseases.[3][4]
It is a mouse monoclonal antibody directed against the alpha chain of the protein lymphocyte function-associated antigen 1 which is involved in immune reactions.[1]
References
- 1 2 Martin, X; Da Silva, M; Virieux, SR; Hadj Aissa, A; Buffet, R; Tiollier, J; Dubernard, JM (2000). "Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation". Transplantation proceedings. 32 (2): 481. doi:10.1016/S0041-1345(00)00849-6. PMID 10715487.
- ↑ Crétolle-Vastel, C; Camby, C; Cerf-Bensussan, N; Cavazzana-Calvo, M; Fischer, A; Révillon, Y; Sarnacki, S (1999). "Role of calcineurin-dependent drugs on the immunosuppressive effect induced by the anti-LFA-1 antibody in a fetal intestinal transplantation model in mice". Chirurgie; memoires de l'Academie de chirurgie. 124 (5): 503–10. PMID 10615777.
- ↑ Whitcup, SM; Chan, CC; Kozhich, AT; Magone, MT (1999). "Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis". Clinical immunology (Orlando, Fla.). 93 (2): 107–13. doi:10.1006/clim.1999.4775. PMID 10527686.
- ↑ Corbascio, M; Mahanty, H; Osterholm, C; Qi, Z; Pearson, TC; Larsen, CP; Freise, CE; Ekberg, H (2002). "Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice". Transplantation. 74 (1): 35–41. doi:10.1097/00007890-200207150-00007. PMID 12134096.
This article is issued from Wikipedia - version of the 9/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.